Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CRIS, Curis (formerly CBMI) -- Ignore unavailable to you. Want to Upgrade?

To: Lyn Benson who wrote (314)	7/2/2000 8:07:54 PM
From: Edwin S. Fujinaka	Read Replies (1) \| Respond to of 668

I have not been following Sykes, but since they hold the manufacturing and marketing rights to OP-1, I hope that any runup for Sykes is due to optimism on the OP-1 front. I believe that I heard that Sykes is actually hiring staff in anticipation of approval of OP-1 very soon in at least one of the three targeted markets (Australia, Europe, and the US). Even if OP-1 is wildly successful, I don't suppose that it would be enough to make Curis profitable anytime soon. Does anyone have any projections for the effect of OP-1? Does anyone know the licensing arrangement that CBMI has? Could the royalties be as high as 18%?